MX2020012728A - Medicinas de origen biologico y metodos para incrementar el cumplimiento del paciente. - Google Patents

Medicinas de origen biologico y metodos para incrementar el cumplimiento del paciente.

Info

Publication number
MX2020012728A
MX2020012728A MX2020012728A MX2020012728A MX2020012728A MX 2020012728 A MX2020012728 A MX 2020012728A MX 2020012728 A MX2020012728 A MX 2020012728A MX 2020012728 A MX2020012728 A MX 2020012728A MX 2020012728 A MX2020012728 A MX 2020012728A
Authority
MX
Mexico
Prior art keywords
methods
bio
patient compliance
medicines
compounds
Prior art date
Application number
MX2020012728A
Other languages
English (en)
Inventor
David Sudolsky
Original Assignee
Anellotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anellotech Inc filed Critical Anellotech Inc
Publication of MX2020012728A publication Critical patent/MX2020012728A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Abstract

Las medicinas que se usan para tratar enfermedades se hacen convencionalmente a partir de materiales de inicio que se derivan de combustibles fósiles y por lo tanto no contienen esencialmente 14C. En la presente invención, las medicinas se pueden derivar parcial o completamente de fuentes biológicas y por lo tanto contienen aproximadamente una parte por trillón (ppt) de 14C. Se ha descubierto que estos compuestos son superiores para el tratamiento de una enfermedad debido a que se ha descubierto sorprendentemente que incrementan de manera sustancial el cumplimiento del paciente. También se dan a conocer compuestos y métodos para usar compuestos farmacéuticamente activos parcial o completamente de origen biológico para rastrear metabolitos.
MX2020012728A 2018-05-28 2019-05-28 Medicinas de origen biologico y metodos para incrementar el cumplimiento del paciente. MX2020012728A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862677161P 2018-05-28 2018-05-28
PCT/US2019/034227 WO2019231937A1 (en) 2018-05-28 2019-05-28 Bio-based medicines and methods of increasing patient compliance

Publications (1)

Publication Number Publication Date
MX2020012728A true MX2020012728A (es) 2021-04-28

Family

ID=68698453

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012728A MX2020012728A (es) 2018-05-28 2019-05-28 Medicinas de origen biologico y metodos para incrementar el cumplimiento del paciente.

Country Status (10)

Country Link
US (1) US20220226310A1 (es)
EP (1) EP3801484A4 (es)
JP (1) JP2021525748A (es)
KR (1) KR20210015827A (es)
CN (1) CN112384209A (es)
AU (1) AU2019277154A1 (es)
BR (1) BR112020024205A2 (es)
CA (1) CA3099916A1 (es)
MX (1) MX2020012728A (es)
WO (1) WO2019231937A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
IT1275905B1 (it) * 1995-03-14 1997-10-24 Indena Spa Frazioni polifenoliche di te', loro uso e formulazioni che le contengono
WO2007095262A2 (en) * 2006-02-10 2007-08-23 Dupont Tate & Lyle Bio Products Company, Llc Bio-derived 1,3-propanediol and its conjugate esters as natural and non irritating solvents
US20090169633A1 (en) * 2007-12-31 2009-07-02 Ta-Ping Liao Oral particle including pseudoephedrine hydrochloride and cetirizine dihydrochloride
US20170073465A1 (en) * 2014-02-28 2017-03-16 Michigan Molecular Institute Sustained release composition using biobased biodegradable hyperbranched polyesters
US9044390B1 (en) * 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
CN105461731B (zh) * 2014-08-07 2017-05-24 富力 连翘脂素布洛芬酯、其制备及其应用
CN104546772B (zh) * 2015-01-22 2017-07-28 鲁南贝特制药有限公司 一种盐酸西替利嗪片

Also Published As

Publication number Publication date
AU2019277154A1 (en) 2020-11-26
US20220226310A1 (en) 2022-07-21
CA3099916A1 (en) 2019-12-05
EP3801484A4 (en) 2022-06-29
EP3801484A1 (en) 2021-04-14
WO2019231937A1 (en) 2019-12-05
BR112020024205A2 (pt) 2021-02-17
CN112384209A (zh) 2021-02-19
JP2021525748A (ja) 2021-09-27
KR20210015827A (ko) 2021-02-10

Similar Documents

Publication Publication Date Title
MX2020003351A (es) Metodos, composiciones y elementos implantables que comprenden celulas activas.
MX2019013954A (es) Inhibidores covalentes de kras.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
MX2023006541A (es) Formulaciones de dosis fija.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022016422A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2019007641A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
MX2019012884A (es) Terapia de combinacion.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
PH12021550872A1 (en) Therapeutic compounds
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EP4233913A3 (en) Improved bromocriptine formulations
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
MX2021005423A (es) Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos.
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.